The WHO announces treatment for excessive bleeding after childbirth

Martins Ifijeh

The World Health Organization (WHO), together with Ferring and MSD for mothers, found a cure for postpartum hemorrhage (PPH), otherwise known as excessive bleeding after childbirth, which is the most common cause of maternal death in developing countries like Nigeria. In a clinical study conducted by the WHO Department of Reproductive Health and Research, including the UNDP-UNFPA-UNICEF-WHO-World Bank Special Program for Research, Development and Research Training in Human Reproduction (HRP), using Thermostable carbetocine of Ferring. funded by MSD for mothers, it was discovered that carbetocin was as effective as oxytocin in preventing excessive bleeding after badl delivery.

According to the WHO, the revolutionary innovation, which was published in the New England Journal of Medicine (NEJM) was recently conducted on nearly 30,000 women in Nigeria and in nine other income countries low or intermediate.

"Thermostable carbetocin remains effective at high temperature, a response to the limitation of oxytocin that must be stored and transported at 2-8 ° C," said the WHO.

Studies conducted in Nigeria and in other developing countries have revealed a degradation and a loss of efficacy of oxytocin blisters, which could be due to storage and distribution conditions, as well as to the use of oxytocin blisters. where the need for the thermostable carbetocin product.

According to the Chief Medical Officer, Ferring Pharmaceuticals, Prof. Klaus Dugi, the data show that thermostable carbetocin remains effective for at least three years "This has the potential to save thousands of women in Nigeria and in other developing countries where 99% of PPH-related deaths occur, and where refrigeration of drugs can be difficult to achieve and maintain.

"The WHO publication concludes that the study should inform care in countries where transportation and cold chain storage are difficult to achieve." We will now work with the US Department of Health. WHO and MSD for mothers to make thermostable carbetocin available in countries where it is needed most, thus protecting women and families around the world. "

then making affordable thermostable carbetocin, adding that Ferrings will ensure that it is available in low- and middle-income countries that have a heavy burden of maternal mortality